TU
ARRY

TDAM USA’s Array Biopharma Inc ARRY Stock Holding History

TDAM USA’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-11,440
Closed -$52K – 352
2014
Q2 		$52K Sell
11,440
-2
-0% -$8 ﹤0.01% 323
2014
Q1 		$54K Hold
11,442
– – ﹤0.01% 322
2013
Q4 		$57K Sell
11,442
-558
-5% -$3.04K ﹤0.01% 308
2013
Q3 		$75K Buy
+12,000
New +$71.3K ﹤0.01% 295

Other funds holding ARRY

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TDAM USA's ARRY Position: Q3 2014 in Review

TDAM USA sold out of Array Biopharma Inc (ARRY) in Q3 2014, closing a stake of 11,440 shares — an estimated $52K sold.

TDAM USA first reported a position in ARRY in Q3 2013 and held it in 4 quarters. The position peaked at $75K in Q3 2013. 112 funds tracked by Wall St. Rank hold ARRY as of Q3 2014.

  • TDAM USA reported no remaining Array Biopharma Inc position as of Q3 2014 after selling out during the quarter.
  • TDAM USA sold 11,440 Array Biopharma Inc shares in Q3 2014, an estimated $52K.
  • TDAM USA first reported a position in Array Biopharma Inc in Q3 2013 and held it in 4 quarters.
  • TDAM USA's Array Biopharma Inc position peaked at $75K in Q3 2013.
  • 112 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2014.

Based on TDAM USA's 13F filing for Q3 2014, filed 6 Nov 2014.